Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224120 · ClinicalTrials.gov registry record · Phase 3
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
A Phase 3 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 462
- Enrollment target
NCT00224120 is a Phase 3 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 462 participants.
The verdict
NCT00224120, a Phase 3 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 462 participants
- Enrollment target
Study Summary
A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
Interventions
- OTHER Placebo
- DRUG Silodosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224120
The ClinicalTrials.gov registry entry for NCT00224120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00224120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224120 about?
NCT00224120 is a clinical study titled "A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo". A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
What is the current status of trial NCT00224120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 462 participants. The study started on 2005-05. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00224120?
The interventions under investigation include: Placebo (OTHER), Silodosin (DRUG).
Who is sponsoring clinical trial NCT00224120?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.